The upgrade centres on new machinery and advanced technology designed to expand capacity and sharpen turnaround times in increasingly competitive flexible packaging markets.
This is an exciting and meaningful milestone for GRIN Therapeutics
The trial’s primary goal is to evaluate vipoglanstat’s effect on endometriosis-related pain during non-menstrual days
The LIFT-PD study will enroll 75 Parkinson’s patients experiencing apathy across 16 sites in Germany, Bulgaria, Poland and Spain
Glucon-D maintained its leadership position with a 59% MAT market share
LOTTE Biologics will provide advanced manufacturing services for monoclonal antibody intermediates and their conjugates
The multicenter study will enroll 75 patients across 16 sites in Germany, Bulgaria, Poland, and Spain
The trial will evaluate the efficacy and safety of IPX203 versus immediate-release levodopa/carbidopa
The company has unveiled the results of pirtobrutinib from its BRUIN CLL-313 study
Winlevi is authorized in EU for the treatment of acne vulgaris
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
